<DOC>
	<DOCNO>NCT01865786</DOCNO>
	<brief_summary>This prospective , observational study describe pregnancy outcome among HIV-1 uninfected pregnant woman take emtricitabine ( FTC ) /tenofovir disoproxil fumarate ( TDF ) ( TruvadaÂ® ) pre-exposure prophylaxis ( PrEP ) indication nest Antiretroviral Pregnancy Registry ( APR ) . Information subject provide APR prospectively ( prior outcome pregnancy know ) healthcare provider , follow-up obtain healthcare provider follow determination pregnancy outcome .</brief_summary>
	<brief_title>A Prospective , Observational Study Pregnancy Outcomes Among Women Exposed Truvada PrEP Indication</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Key Pregnant woman Part prospective arm APR Target Group Inclusion Criteria HIV1 Negative Choosing remain FTC/TDF PrEP pregnancy , Choosing discontinue FTC/TDF PrEP pregnancy Comparison Group Inclusion Criteria HIV1 Positive On antiretroviral therapy Key This observational nested study monitor report exposure without intervention/exclusion . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>FTC/TDF</keyword>
	<keyword>Truvada</keyword>
	<keyword>PrEP</keyword>
	<keyword>Antiretroviral Pregnancy Registry</keyword>
</DOC>